in 2015, the oncogenex pharmaceuticals company has been a major focus of research and research efforts in the last few years. the company has been able to progress in the development of custirsen and its lead product candidate, appatorsen. in this article, we will provide an update on our clinical programs and anticipate anticipated milestones through the end of this year and into 2016.